Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METRONIDAZOLE

All products: general benefit

M-Metronidazole · DIN 02519755 · 500mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Metronidazole · DIN 02519755 Manufacturer: Mantra Pharma Inc.; listing date 2022-04-29 Daily cost (source): $0.8217 Health Canada: Marketed since 2022-03-04 · brand M-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Metronidazole: Formulary list price $0.2739/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2739 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100899 · Verify on the e-Formulary ↗ (DIN 02519755)

Source record
DIN 02519755: M-Metronidazole Raw flags: sec3=Y Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id MAT Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.2739; ministry $0.2739 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519755 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100899
Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739 Auro-Metronidazole · DIN 02470284 · $0.2739 Flagyl · DIN 01926853 · not recorded Metronidazole · DIN 02518767 · $0.2739 Metronidazole · DIN 02534592 · $0.2739 PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519755
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:32 Trichomonacides) and how they are covered
No products matched this class search: “08:32”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for: Bacterial Vaginosis Metronidazole is indicated for the treatment of bacterial vaginosis. Protozoal Infections • Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas vaginalis). • Hepatic and intestinal amebiasis. • Giardiasis. Bacterial Infections Treatment: Culture and susceptibility studies should be performed to determine the causative organisms and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological findings, therapy may be started while awaiting the results of these tests. However, modification of the treatment may be necessary once these results become available. In mixed aerobic and anaerobic infections, consideration should be given to the concomitant administration of an antibiotic appropriate for the treatment of the aerobic component of the infection. See 7 Warnings and Precautions, General. Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections (some with abscesses) caused by anaerobic bacteria. Prophylaxis: If there are signs of infections, spe… https://pdf.hres.ca/dpd_pm/00084527.PDF PM date: 2026-04-20 Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.